Cost-effectiveness Analysis of Ocrelizumab for the Treatment of Relapsing and Primary Progressive Multiple Sclerosis in Portugal

OBJECTIVES: Ocrelizumab demonstrated significant clinical benefit for the treatment of relapsing (RMS) and primary progressive (PPMS) multiple sclerosis (MS), an incurable disease characterized by disability progression. This study evaluated the clinical and economic impact of ocrelizumab relative t...

Descripción completa

Detalles Bibliográficos
Autores principales: Martins, Paulo, Vandewalle, Björn, Félix, Jorge, Capela, Carlos M., Cerqueira, João J., Salgado, António V., Ferreira, Diana G., Monteiro, Isabel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043078/
https://www.ncbi.nlm.nih.gov/pubmed/36454397
http://dx.doi.org/10.1007/s41669-022-00381-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043078/
https://www.ncbi.nlm.nih.gov/pubmed/36454397
http://dx.doi.org/10.1007/s41669-022-00381-z

Ejemplares similares